Dr. Baoxu Pang

I received my PhD with Cum Laude from the Netherlands Cancer Institute, defining a novel mode of action of a broadly used anti-cancer drug, doxorubicin, and its anthracycline members. I discovered that doxorubicin and other anthracycline members can also destabilize nucleosomes and evict histones from particular chromatin regions upon intercalating into the chromatin. As a result, DNA damage response is attenuated and the epigenome of the cell is deregulated. After brief period of post-doc training at the Netherlands Cancer Institute, I moved to the Department of Genetics, Stanford University in the US, where I developed unique genome-wide screen systems to study the function of the non-coding genome. In 2018 I started my research group at the Department of Cell and Chemical Biology. I was awarded the Antoni van Leeuwenhoek Prize from NKI-AvL, the Academic Excellence Award from China, Gisela Thier Fellowship, and KWF/Alpe Young lnvestigator Grant.


  • Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.

    Pang B*, Qiao X*, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W and Neefjes J.

    Nature Communications. 2013;4:1908

  • Chemical profiling of the genome with anti-cancer drugs defines target specificities.

    Pang B*†, de Jong J*, Qiao X*, Wessels LFA†, Neefjes J†.

    Nature Chemical Biology. 2015, 11, 472–480.

  • Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer.

    Wijdeven R*, Pang B*, van der Zanden S, Qiao X, Blomen V, Hoogstraat M, Lips EH, Janssen J, Wessels LFA, Brummelkamp T, Neefjes J.

    Cancer Research. 75(19) October 1, 2015.


Collaborate with us

Looking for information on one of our topics, a new place to conduct your research or experienced research to join forces with?  Feel free to contact us.!

Read more